Nymox Pharmaceutical Corp. buy melinda
Startpreis
02.11.18
/
50%
1,78 €
Kursziel
18.01.19
2,07 €
Rendite (%)
18,78 %
Endpreis
18.01.19
2,11 €
Zusammenfassung
Diese Einschätzung wurde am 18.01.19 mit einem Endkurs von 2,11 € beendet. Mit einer Rendite von 18,78 % entwickelte sich die Einschätzung BUY ganz nach Plan. melinda hat 50% Zuversicht bei dieser Einschätzung
Finanztrends
Rendite ohne Dividenden (%)
Name | 1W | 1M | 1J | 3J |
---|---|---|---|---|
Nymox Pharmaceutical Corp. | - | - | - | - |
iShares Core DAX® | 1,52 % | 3,46 % | 25,97 % | 21,60 % |
iShares Nasdaq 100 | 1,24 % | 2,98 % | 31,32 % | 39,18 % |
iShares Nikkei 225® | 2,81 % | 2,74 % | 19,60 % | 5,12 % |
iShares S&P 500 | 0,40 % | 2,19 % | 28,62 % | 40,35 % |
Kommentare von melinda zu dieser Einschätzung
In der Diskussion Nymox Pharmaceutical Corp. diskutieren
SecteurRecherche biotechnologique et médicale Agenda 15/11 Publication de résultats
Operates as a biopharmaceutical company, which specializes in the research and development of products for the aging population
Nymox Pharmaceutical Corp.operates as a biopharmaceutical company, which engages in the research and development on products for the aging population.
Its products include NicAlert and TobacAlert, and the NX-1207 for the treatment of low-grade localized prostate cancer.
It operates through the following geographical segments: Canada, United States, and Europe.
The company was founded by Paul Averback on May 30, 1995 and is headquartered in Nassau, the Bahamas.
Nymox Pharmaceutical Corp.operates as a biopharmaceutical company, which engages in the research and development on products for the aging population.
Its products include NicAlert and TobacAlert, and the NX-1207 for the treatment of low-grade localized prostate cancer.
It operates through the following geographical segments: Canada, United States, and Europe.
The company was founded by Paul Averback on May 30, 1995 and is headquartered in Nassau, the Bahamas.
Nombre d'employés : 2 personnes.
(Zielkurs erreicht)
Beendete Einschätzungen von melinda zu Nymox Pharmaceutical Corp.
Nymox Pharmaceutical Corp.
Startkurs
Kursziel
Rendite (%)
3,70 €
24.07.16
24.07.16
4,06 €
12.08.16
12.08.16
-43,17 %
12.08.16
12.08.16